Reneuron Share Discussion Threads

[bantam175] 16/9/2020 14:58

Only downside with this that I'm aware of is the tie ins with China. Could prove troublesome with US marketing.

(Unless Trump is gone in November of course).

[rayrac] 16/9/2020 11:14

Yep, up to tricks...or news on the way.

[rayrac] 16/9/2020 09:50

Mm’s trying to shake things up a bit? Still got to be brave

[rayrac] 16/9/2020 09:26

Here we go...a failure somewhere? Better out than in, for the brave only?

[whatno] 08/9/2020 17:24

Things are very quiet but the AGM is on the 10th and Hunt has previously stated that there will be an update on the ph2a extension trial soon. My guess is that they will announce full details of the testing including locations and schedule. I suspect they will also say in the update that they have treated the first patient in the US.

[pawelkordala] 08/9/2020 10:38

Volume is super low. This price action means nothing. It was pushed down by 50% by some small retail investors who are not patient enough to wait for the new data from clinical trails. Some people probably prefer hot covid stocks...

[dennisbergkamp] 07/9/2020 18:20

Crazy that in all the mad dash for the biotech plays, this is going the wrong way!

Maybe they need to add the phrase "Covid-19" to their PR campaigns!

D

[bonzo] 07/9/2020 17:49

Really sad to see this great company going down the pan...

[rotors] 28/8/2020 09:41

Thanks for a very interesting link MMM

[malcolmmm] 27/8/2020 23:33

Nice presentation here. Good one on ORPH also.

[pawelkordala] 27/8/2020 07:23

I think people need to be patient on this one. They will probably deliver, but they just need more data.

[bg23] 26/8/2020 09:21

Edison u/g the value of the company to £170m from £107m


hxxps://www.edisongroup.com/publication/exploiting-the-potential-of-cell-therapy/27598

[brianking1pin] 03/8/2020 12:38

Problem is we need to get out of this downward trend .

[onceaday] 02/8/2020 21:53

There are a number of very large pharmas trying to enhance their portfolios in optometry. For the phase2a extension study,RENE have clearly taken feedback from some of these in designing the trial efficacy signals. They have world class expertise in the.two Principal Investigators and the influence tne PIs will have with big pharma should be very significant in sealing an early deal. If the results of the extension study are at least as good as the phase 2a then this would equal or exceed results obtained for approved gene therapy products in RP.

I very.much doubt they will have a problem raising additional finamce. My bet is that it will come from a US institutional investor/VC.

[hollywood6] 02/8/2020 21:08

Need multiple Row partners to spread risk here. Hopefully some incoming partners funds to see through any future financial limitations.

[hollywood6] 02/8/2020 21:07

A worry for sure

[small crow] 31/7/2020 10:31

Confidence building in both partners and shareholders with each announcement. Could be well over £3 given a following wind during the next 12 months.

[bantam175] 31/7/2020 09:42

Just a shame that the partnership deal is with a Chinese company given the current climate.

[onceaday] 31/7/2020 09:38

Let's hope they start the ph2a extension study soon. If indeed the company needs to raise.funds then they will be doing all they can to get the share price higher. I suspect they will release an ipdate within one.month of treating a subset of the planned 9 patients if results are "material". Possibly within the.next 90 days.

[brianking1pin] 31/7/2020 09:16

Very good level to be buying at the moment, Just wish that I was able to say that I entered below £1.30. IF only !

[ayl30] 31/7/2020 09:04

Good move this am

[onceaday] 28/7/2020 20:37

That appears to be the case. If you watch some of the jCyte presentations on youtube, the mode of operation is to rescue dying photoreceptors but it is not thought to result in new photoreceptors integrating into the retina. RENE has shown through experiments in pigs eyes that they do get integration after sub-retinal injection. Given that the ph2a study results were dose dependent, we could see improved efficacy due to doubling the dose to 2million cells in the ph2a extension study.

[philh75] 28/7/2020 20:04

Agreed all. Jcyte do not have the cryo formulation, so have a few days rather than 6 months shelf life. Also, Reneuron believe that because of the difference in administration (the layer they go into) they (Jcyte) may not be growing new photoreceptors only providing trophic? support.